TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 217894
Drug: HMG 2250
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG 2250 mg and 3000 mg per day
Study: 31582355
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg for 30 min every 2 weeks)
Study: 31582355
Drug: Chemotherapy (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (paclitaxel 100 mg/m2 once per week for 6 weeks or docetaxel 75 mg/m2 every 3 weeks)
Study: 17086091
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg orally at bedtime for 6 weeks
Study: 17086091
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (12 healthy subjects, no drug administration)
Study: 15276658
Drug: Child Beck
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child Beck Depression Inventory (CBDI) administered to all students
Study: 11034630
Drug: Palliative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palliative radiation therapy with efficient fractionation schedules
Study: 1351183
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 62): unrestricted diet for mothers and infants; no acaricidal treatment.
Study: 27666156
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin epic group (20U of botulinum toxin injection into the lateral epicondyle)
Study: 21471671
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/day
Study: 20164484
Drug: Low-dose platelet
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose platelet transfusion (1.1x10(11) platelets/m2)
Study: 20164484
Drug: Medium-dose platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose platelet transfusion (2.2x10(11) platelets/m2)
Study: 20164484
Drug: Low-dose platelet
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose platelet transfusion
Study: 10360655
Drug: Immunotherapy (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (Group B, n = 14) with weekly injection of streptococcal preparation OK‐432
Study: 1826806
Drug: Enoximone 100
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 100 mg three times a day
Study: 31586784
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg every 6 hours for 24 hours
Study: 31586784
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg every 6 hours for 24 hours
Study: 25504295
Drug: eSTI screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: eSTI screening using a home collection kit and an e-prescription for uncomplicated treatment
Study: 25504295
Drug: Standard clinic-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard clinic-based STI screening and treatment
Study: 21794114
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (perindopril)
Study: 8586825
Drug: Beta-blocker (bisoprolol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (bisoprolol)
Study: 19802538
Drug: Intravenous dripping
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dripping of ganciclovir 10 mg/kg per day
Study: 11228061
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (n = 12)
Study: 11228061
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (GnRH agonist, GnRH agonist plus COC, GnRH agonist plus flutamide)
Study: 1675518
Drug: Topical PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical PUVA
Study: 3287815
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g metronidazole
Study: 6359490
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g metronidazole
Study: 28116433
Drug: Lauromacrogol combined
Normalized name: lauromacrogols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lauromacrogol combined with pingyangmycin injection
Study: 28116433
Drug: Pingyangmycin injection
Normalized name: Pingyangmycin a2
DrugBank: Bleomycin A2 (DB19091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pingyangmycin injection
Study: 24261927
Drug: Treatment satisfaction
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment satisfaction at week 6
Study: 19800931
Drug: Vicoprofen (hydrocodone
Normalized name: Vicoprofen (hydrocodone bitartrate 7.5 MG / ibuprofen 200 MG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicoprofen (hydrocodone bitartrate 7.5mg with Ibuprofen 200mg)
Study: 19800931
Drug: Ibuprofen (200mg)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (200mg)
Study: 1881831
Drug: Verapamil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (3 x 120 mg/24 hr)
Study: 6137859
Drug: Triazolam 0.25
Normalized name: triazolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.25 mg, administered in the morning
Study: 6137859
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered in the morning
Study: 31143442
Drug: 1-day (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day (single dose) cefazolin
Study: 22512898
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg MPH-SR
Study: 20932900
Drug: Monodisperse salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monodisperse salbutamol sulphate aerosols of 1.5, 3 and 6 μm mass median aerodynamic diameter in a cumulative dosing schedule of 10, 20, 40 and 100 μg
Study: 17006439
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH) 1 microg/kg
Study: 16130428
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of phenoterol and ipratropium bromide
Study: 11495172
Drug: Cognitive‐behavioral/skill training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral/skill training therapy (CBT)
Study: 11495172
Drug: Motivational interviewing/supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing/supportive (MIS) therapy
Study: 11495172
Drug: Brief intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief intervention (BI) treatment
Study: 31520741
Drug: Immediate initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immediate initiation of etoposide with antiretroviral therapy (ART)
Study: 28039291
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no anticoagulants)
Study: 25715366
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment (Control)
Study: 10824450
Drug: Placebo 5
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 5 mg t.i.d.
Study: 8003236
Drug: Oral-B P-35
Normalized name: p-chloro-3,5-xylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B P-35
Study: 3548294
Drug: Prophylactic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic heparin treatment (group I)
Study: 15145035
Drug: Arthroscopy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopy with sodium hyaluronate infusion
Study: 8180671
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (0.02-0.05 IU/kg body wt sc daily)
Study: 10896637
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone
Study: 18812659
Drug: valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80 mg/d
Study: 16368298
Drug: valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 160 mg/d
Study: 10960199
Drug: Routine O(2)
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine O(2) therapy (control group)
Study: 8773861
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg.kg‐1 and 5 mg.kg‐1 thiopentone (group MT)
Study: 8773861
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg.kg‐1 (group P)
Study: 8773861
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg.kg‐1 and 5 mg.kg‐1 thiopentone (group LT)
Study: 6499510
Drug: Dantrolene sodium
Normalized name: Dantrolene Sodium
DrugBank: Dantrolene (DB01219)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dantrolene sodium (average dose 165.4 mg/day)
Study: 29547962
Drug: Four open-label
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four open-label placebo pills per day
Study: 19332659
Drug: Physiological sex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological sex steroid replacement (transdermal estradiol and vaginal progesterone)
Study: 19332659
Drug: Standard sex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sex steroid replacement (oral ethinylestradiol and norethisterone)
Study: 15884282
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg oral misoprostol, six hourly for a maximum of four doses
Study: 9084795
Drug: Control treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatments (ZDV or ZDV/zalcitabine)
Study: 22513778
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg/day
Study: 17443465
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B 3 mg/kg per day
Study: 17443465
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B 10 mg/kg per day
Study: 30704697
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600mg twice daily
Study: 30704697
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) with long-acting inhaled bronchodilator(s) but no ICS
Study: 27776269
Drug: Counselor-delivered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselor-delivered treatment (Arm 1)
Study: 23393065
Drug: Dexamethasone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (20 mg orally) with 8 h of isocapnic hypoxia
Study: 17923015
Drug: Gelatin group
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin group (GEL group)
Study: 2539403
Drug: Captopril 12.5
Normalized name: captopril 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5 mg orally three times per day
Study: 25722382
Drug: Tecemotide (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecemotide (in concurrent chemoradiotherapy subgroup)
Study: 25722382
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in concurrent chemoradiotherapy subgroup)
Study: 23430455
Drug: 6-month lifestyle
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month lifestyle intervention for weight loss (weekly group sessions for 6 months, followed by 12 months of biweekly contacts)
Study: 22052225
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg orally once daily on days 5 to 11)
Study: 16391577
Drug: 8.4 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.4 mg/day riboflavin (R group)
Study: 15080016
Drug: Elderberry syrup
Normalized name: Nature's Way Sambucus Elderberry Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elderberry syrup (15 ml, four times a day for 5 days)
Study: 1546818
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup
Study: 9522869
Drug: Glucose-based oral
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-based oral rehydration solution (ORS)
Study: 9076618
Drug: Rice-based oral
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice-based oral rehydration solution (ORS)
Study: 2672871
Drug: Homologous fresh
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homologous fresh frozen plasma (FFP), 2 units (430 +/- 11 ml) given after the end of extracorporeal circulation (ECC)
Study: 342625
Drug: Bivalent influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent influenza A virus vaccines (200 or 400 CCA units of A/New Jersey/8/76 and A/Victoria/3/75)
Study: 23950585
Drug: Natalizumab 300
Normalized name: natalizumab 300 MG in 15 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab 300 mg intravenously once monthly (infusion every 4 weeks)
Study: 19625629
Drug: Palosuran (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palosuran (5 to 2000 mg, oral doses)
Study: 17445284
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g high molecular weight (HMW) BBG
Study: 16330295
Drug: Glyburide/Metformin (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide/Metformin (1.25 mg/250 mg BID for 6 days)
Study: 16330295
Drug: Memantine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (20 mg) and Glyburide/Metformin coadministered
Study: 12167274
Drug: Enfuvirtide (T-20)
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enfuvirtide (T-20) 100 mg bid SC injection
Study: 12167274
Drug: Enfuvirtide (T-20)
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enfuvirtide (T-20) 50 mg bid SC injection
Study: 10203570
Drug: Meal A
Normalized name: Yardley Oatmeal and Almond Bath Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal A (600 g spinach)
Study: 7607966
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation (once daily 1.8‐2.0 Gy)
Study: 7607966
Drug: Hyperfractionated split‐course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionated split‐course irradiation (twice daily 1.6 Gy)
Study: 2393075
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg alfentanil (A3)
Study: 681295
Drug: amoxapine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxapine (300 mg)
Study: 681295
Drug: amitriptyline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: amitriptyline (150 mg)
Study: 31673419
Drug: tofacitinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib monotherapy
Study: 20623180
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (NT)
Study: 20623180
Drug: Pre-chemotherapy sHER2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-chemotherapy sHER2 levels
Study: 20623180
Drug: sHER2 cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: sHER2 cut-off level of 10 ng/ml
Study: 17624687
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose diazepam (40 mg)
Study: 17624687
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose opioid administration (150% normal dose)
Study: 16625983
Drug: Omeprazole group
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole group (1-week omeprazole 20 mg twice daily)
Study: 11307252
Drug: Anolyte neutral
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anolyte neutral cathodic (ANC) (300 mg L‐1 of active chlorine)
Study: 11307252
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anolyte ANC and catholyte
Study: 11307252
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ANC and catholyte
Study: 9122640
Drug: Reduced osmolarity
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced osmolarity oral rehydration salt (ORS) solution (sodium 67, potassium 20, chloride 66, citrate 7, glucose 89 mmol/l, osmolality 249 mOsmol/kg)
Study: 9122640
Drug: Reduced osmolarity
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced osmolarity oral rehydration salt (ORS) solution
Study: 24271261
Drug: Synbiotic food
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic food (1 × 10⁷ CFU Lactobacillus sporogenes and 0.04 g inulin HPX/g) consumed two times a day for 9 weeks
Study: 23394513
Drug: Fexofenadine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine at fourfold dose
Study: 18771886
Drug: Endovascular revascularization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular revascularization and best medical treatment (group A)
Study: 10551919
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg (group-M)
Study: 8916058
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine premedication
Study: 8916058
Drug: No morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No morphine
Study: 21041485
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment in pregnancy (IPTp)
Study: 15491374
Drug: Bifidobacterium breve
Normalized name: Bifidobacterium Breve
DrugBank: Bifidobacterium breve (DB16549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium breve (B. breve) supplement, 1.6 x 10(8) cells, twice a day, starting 24 hours after birth (Group B)
Study: 15491374
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group C), no supplement
Study: 12575591
Drug: Compound Salvia
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Salvia Injection (CSI) added to conventional treatment
Study: 7887107
Drug: LF+TEA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LF+TEA group receiving low dose fentanyl (15 micrograms.kg‐1) + TEA
Study: 31477164
Drug: Peer education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer education intervention (up to two groups per puskesmas, led by trained individuals with diabetes, sessions held monthly for 18 months)
Study: 25792638
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg daily) and bevacizumab (15 mg·kg(‐1) on day 1, every 3 weeks)
Study: 25792638
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg·m(‐2) on day 1, every 3 weeks) and gemcitabine (1250 mg·m(‐2) on days 1 and 8, every 3 weeks) and bevacizumab (15 mg·kg(‐1) on day 1, every 3 weeks)
Study: 19840379
Drug: Sulfasalazine (1.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (1.5, 3, 4.5, or 6 grams daily)
Study: 16930141
Drug: Pegfilgrastim (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (6 mg single dose on day 1 post-transplant)
Study: 15191542
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of benzophenone-3 (BP-3)
Study: 15191542
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of octyl-methoxycinnamate (OMC)
Study: 15191542
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 3-(4-methyl-benzylidene) camphor (4-MBC)
Study: 15191542
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of sunscreens (BP-3, OMC, 4-MBC)
Study: 9443587
Drug: Dopamine precursor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine precursor (L-DOPA) - 4 mg/kg Sinemet
Study: 31851017
Drug: Histopathological evaluation
Normalized name: STOMATOLOGICAL PREPARATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histopathological evaluation with high-density laser treatment
Study: 30728003
Drug: ART+C (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART+C (1 mg/kg corticosteroids)
Study: 8318320
Drug: Bupivacaine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine infusion
Study: 9850268
Drug: Intraoperative MMC
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative MMC (0.2 mg/ml for 3 min) with post-operative 5-FU (5 mg in 0.5 ml of balanced salt solution) and ocular massage (OM)
Study: 9850268
Drug: Standard trabeculectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard trabeculectomy with post-operative 5-FU (5 mg in 0.5 ml of balanced salt solution) and ocular massage (OM)
Study: 2664728
Drug: Meclofenomate 100
Normalized name: meclofenamate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclofenomate 100 mg t.i.d. for 5 days
Study: 923067
Drug: Tocainide (400-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide (400-600 mg loading doses, maintenance doses every 12 hours)
Study: 923067
Drug: Tocainide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide (400 to 1100 mg every 12 hours during cross-over)